Investigating how neprilysin inhibition affects heart and metabolic health in Black individuals
The Effects of Neprilysin Inhibition on Cardiometabolic Health in Black Individuals
This study is looking at how a specific medication might help improve heart and metabolic health in Black individuals who are at risk for insulin resistance, by checking if it can boost certain helpful substances in the body.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-11082417 on NIH RePORTER |
What this research studies
This research explores the relationship between neprilysin inhibition and cardiometabolic health specifically in Black individuals, who are at a higher risk for insulin resistance and related diseases. The study will utilize sacubitril/valsartan, a medication that inhibits neprilysin, to potentially enhance levels of natriuretic peptides and GLP-1, which are important for regulating metabolism. By measuring changes in insulin sensitivity and energy expenditure, the research aims to determine if this treatment can improve overall cardiometabolic health in the targeted population.
Who could benefit from this research
Good fit: Ideal candidates for this research are Black individuals aged 21 and older who are experiencing issues related to insulin resistance or cardiometabolic health.
Not a fit: Patients who are not Black or those under 21 years old may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for cardiometabolic diseases in Black individuals, potentially reducing their risk of related health complications.
How similar studies have performed: Previous research has indicated that neprilysin inhibition may have beneficial effects on metabolic health, suggesting that this approach could be promising for the targeted population.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Arora, Pankaj — University of Alabama at Birmingham
- Study coordinator: Arora, Pankaj
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.